PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1540304-1	1992	Folinic acid (15 mg bid, po) was administered in a two week, double-blind, placebocontrolled, cross over clinical trial in 5 patients with Parkinson"s disease (Hoehn and Yahr stage I or II).	Leucovorin	0-12	BH3 interacting domain death agonist	Homo sapiens	20-23	
11099325-4	2000	Two weeks later, patients began treatment with eniluracil (20 mg) and leucovorin (15 mg) (PO bid on days 1 through 3) and 5-FU (10 to 15 mg/m(2) PO bid on day 2).	Leucovorin	70-80	BH3 interacting domain death agonist	Homo sapiens	93-96	
11099325-9	2000	CONCLUSION: The recommended oral dosage of 5-FU (10 mg/m(2) PO bid) given with eniluracil and leucovorin is approximately 115-fold lower than the reference dosage for 24-hour infusional 5-FU.	Leucovorin	94-104	BH3 interacting domain death agonist	Homo sapiens	63-66